family with sequence similarity 207 member B, pseudogeneGenealiases: []
Q-omics provides the consensus-scored FAM207BP profile across patient tissues and cancer cell-line models. FAM207BP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, FAM207BP is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, FAM207BP RNA expression shows 16,662 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, COAD, and ACC as cancer lineages where FAM207BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM207BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM207BP survival associations across molecular data types. FAM207BP RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM207BP RNA expression–survival associations across cancer types. High FAM207BP expression shows unfavorable associations in LUAD, LIHC, ACC, MESO, LAML and HNSC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for FAM207BP RNA expression.
This table summarizes FAM207BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM207BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM207BP shows higher tumor expression in COAD, KIRC, HNSC, LIHC, LUAD and LUSC. The COAD box plot shows higher FAM207BP RNA expression in tumor versus normal tissue (log2 FC = +0.551, t-test p < 0.001).
This table shows molecular features associated with FAM207BP in patient tissues and cancer cell lines. In patient samples, FAM207BP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
